Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 1.00 |
| ▸ | PDK4 | Q16654 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518706 | 1.00 | PDK2 (1.00) | PDK2PDK4LMNAAKR1B1PGR | |
| SCHEMBL7134735 | 0.84 | PDK2 (0.71) | PDK2PDK4LMNAPGRKMT2A | |
| SCHEMBL9591821 | 0.83 | PDK2 (0.71) | PDK2PDK4LMNAPGRKMT2A | |
| SCHEMBL31911 | 0.80 | PDK2 (0.67) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL29371027 | 0.80 | PDK2 (0.67) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL10690527 | 0.80 | PDK2 (0.67) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL2264508 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL2313519 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2264504 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL2266448 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAAKR1B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 943 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118223047-A | Method for synthesizing N-Mannich alkali compound by taking methanol as carbon source under electric assistance | 天津科技大学 | 2024-06-21 | — | — | CN | claimed |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | claimed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| CN-109743875-A | The inhibitor of MENIN-MLL interaction | 生命医药公司 | 2019-05-10 | — | — | CN | claimed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | claimed |
| CN-106543148-B | A kind of substitution Oxoindole-benzimidazole salt compound and preparation method thereof | 云南大学 | 2019-04-16 | — | — | CN | claimed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | claimed |
| CN-104114557-B | 8-substituted 2-amino- [1,2,4] triazolo [1,5-a ] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors | 默克专利股份公司 | 2017-10-24 | — | — | CN | claimed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | claimed |
| CN-106543148-A | It is a kind of to replace Oxoindole-benzimidazole salt compound and preparation method thereof | 云南大学 | 2017-03-29 | — | — | CN | claimed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | claimed |
| EP-2209373-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | claimed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | claimed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| WO-2009045386-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
| CN-101166722-A | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| CN-101029042-A | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-09-05 | — | — | CN | claimed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | PDK2 2087/4885PDK4 2990/4885LMNA 4495/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | PDK2 2087/4885PDK4 2990/4885LMNA 4495/4885 |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | PDK2 2087/4885PDK4 2990/4885LMNA 4495/4885 |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | PDK2 1667/4885PDK4 2899/4885LMNA 4653/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | PDK2 2087/4885PDK4 2990/4885LMNA 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.